Clareo Health | The Fecal Immunoassay Occult Blood Test Combined With Calprotectin Sequential Linkage Imaging Endoscopy Screening Strategy for Monitoring Tumor Changes Associated With Long-duration Ulcerative Colitis
The Fecal Immunoassay Occult Blood Test Combined With Calprotectin Sequential Linkage Imaging Endoscopy Screening Strategy for Monitoring Tumor Changes Associated With Long-duration Ulcerative Colitis
Definite diagnosis of ulcerative colitis by clinical, endoscopic, and pathological criteria.
Meeting at least one of the following high-risk criteria (with first onset of mucopurulent bloody stool as the starting time): E1/E2 disease duration \>10 years; E3 disease duration \>8 years; with primary sclerosing cholangitis (PSC); first-degree family history of colorectal cancer; history of colorectal neoplasia resected.
Discontinued any form of glucocorticoids for at least 4 weeks prior to enrollment.
In clinical remission at enrollment (stool frequency score \<3, rectal bleeding score = 0).
Able to understand the study, voluntarily participate, and sign written informed consent.
You may not be if
Presence of other gastrointestinal diseases or tumors.
Severe comorbidities (e.g., cardiopulmonary insufficiency, hepatic or renal failure) that may affect study results or preclude tolerance of endoscopy.
Currently taking antiplatelet or anticoagulant medications (aspirin, warfarin, rivaroxaban, etc.).
